Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2007-007536-25-NL
EUCTR2007-007536-25-NLActive, not recruitingPhase 1

Randomized, Open-label study of Dabigatran Etexilate, a Novel, oral, Direct Thrombin-inhibitor in clinical development, in Elective Percutaneous Coronary Intervention. (D-Fine) - D-Fine

Boehringer Ingelheim b.v.0 sites50 target enrollmentStarted: June 2, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients are eligible for the study if they are:
  • •1.between 18 and 85 years of age, both included
  • •2.due to undergo an elective (non urgent) PCI on one or multiple lesions in the native coronary vessel(s) via a femoral approach
  • •3.if they provide informed consent.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Patients are excluded from this study if:
  • •1.Not a candidate for PCI. Lesion specific conditions:
  • •-Left main disease
  • •-Chronic Total Occlusions
  • •-Bifurcation lesions, or hemodynamic sidebranch
  • •-Three vessel disease requiring treatment of more than 2 lesions (no staging is allowed)
  • •-PCI for restenosis.
  • •2.New York Heart Association class III or IV congestive heart failure.
  • •3.Hemodynamic instability.
  • •4.Severe hypertension not adequately controlled by antihypertensive therapy at the screening visit (Blood Pressure > 180/110mmHg).
  • •5.Significant mitral or aortic valves disease.
  • •6.Increased bleeding risk:
  • •-Ischemic stroke within the last year or history of any previous hemorrhagic stroke, or intracranial aneurysm
  • •-Recent (< 1 month) trauma or major surgery (including bypass surgery) in the last 3 months
  • •-Symptomatic or endoscopically documented ulcer disease in the previous 30 days
  • •-Active or recent (< 3 months) major, minor TIMI definition-bleeding
  • •-Impaired hemostasis: Thrombocytopenia ( platelet count <100*109) or active bleeding disorder
  • •-Anticoagulant (heparin, coumarin) use; international normalized ratio >1.5
  • •-Use of oral non steroidal inflammatory drugs (NSAID) within 12 hrs prior to PCI
  • •-Past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand’s disease or hemophillia; acquired bleeding disorders; and unexplained clinically significant bleeding disorders)
  • •7.Thrombolytic therapy within 24 hours preceding randomization
  • •8.Severe renal impairment (e.g. known creatinine clearance < 30 mL/min (GFR -assessed by the Modification of Diet in Renal Disease (MDRD) study equation) or clinical markers of severe renal impairment) [R02-2429] [R02-2529]
  • •9.Known liver disease (e.g. known high concentrations of liver enzymes (more than twice the ULN))
  • •10.Pre-menopausal (last menstruation < 1 year prior to screening) sexually active women who: are pregnant or nursing or are not surgically sterile or are of child bearing potential and not practicing an acceptable method of birth control, (acceptable methods include intrauterine devices (IUD), oral, implantable or injectable contraceptives, double barrier or vasectomised partner)
  • •11.A pregnancy test indicating pregnancy in a woman of childbearing potential at screening (Visit 1)
  • •12.Treatment with other investigational drugs or devices within 30 days before enrolment or planned use of investigational drugs or devices during the study
  • •13.Use of quinidine
  • •14.Known allergy, hypersensitivity or contraindication to clopidogrel, aspirin.
  • •15.Inability to give informed consent or high likelihood of being unavailable for follow-up
  • •16.Inability or unwillingness to perform 7-14 day follow up
  • •17.Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g. drug addiction, alcohol abuse).

Investigators

Sponsor
Boehringer Ingelheim b.v.

Similar Trials

Active, not recruiting
Phase 1
ninterrupted dabigatran etexilate in comparison to uninterrupted warfarin in pulmonary vein ablation (RE-CIRCUIT)Patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation for atrial fibrillationMedDRA version: 18.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 18.0Level: PTClassification code 10043634Term: Thrombosis prophylaxisSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2014-003890-40-ESBoehringer Ingelheim España, S.A.795
Active, not recruiting
Phase 1
ninterrupted dabigatran etexilate in comparison to uninterrupted warfarin in pulmonary vein ablation (RE-CIRCUIT)Patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation for atrial fibrillationMedDRA version: 18.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 18.1Level: PTClassification code 10043634Term: Thrombosis prophylaxisSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2014-003890-40-NLBoehringer Ingelheim bv795
Active, not recruiting
Phase 1
ninterrupted dabigatran etexilate in comparison to uninterrupted warfarin in pulmonary vein ablation (RE-CIRCUIT)Patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation for atrial fibrillationMedDRA version: 18.1 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersMedDRA version: 18.1 Level: PT Classification code 10043634 Term: Thrombosis prophylaxis System Organ Class: 10042613 - Surgical and medical procedures
EUCTR2014-003890-40-GBBoehringer Ingelheim Limited704
Active, not recruiting
Phase 1
ninterrupted dabigatran etexilate in comparison to uninterrupted warfarin in pulmonary vein ablation (RE-CIRCUIT)Patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation for atrial fibrillationMedDRA version: 17.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 17.1Level: PTClassification code 10043634Term: Thrombosis prophylaxisSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2014-003890-40-ITBoehringer Ingelheim Italia S.p.A.795
Active, not recruiting
Phase 1
ninterrupted dabigatran etexilate in comparison to uninterrupted warfarin in pulmonary vein ablation (RE-CIRCUIT)Patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation for atrial fibrillationMedDRA version: 19.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.0Level: PTClassification code 10043634Term: Thrombosis prophylaxisSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2014-003890-40-DEBoehringer Ingelheim Pharma GmbH & Co. KG795